Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avenue Therapeutics (ATXI – Research Report) and Inovio Pharmaceuticals (INO – Research Report).
Avenue Therapeutics (ATXI)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Avenue Therapeutics yesterday and set a price target of $0.75. The company’s shares closed last Wednesday at $0.17, close to its 52-week low of $0.13.
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of
Avenue Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $0.75.
See the top stocks recommended by analysts >>
Inovio Pharmaceuticals (INO)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals. The company’s shares closed last Wednesday at $0.53, close to its 52-week low of $0.32.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of
Inovio Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $0.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATXI:
- Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
- Avenue announces completion of enrollment in Phase 1b/2a trial of AJ201
- Avenue Therapeutics initiated yesterday with a Buy at Maxim
- Avenue Therapeutics initiated with bullish view at Maxim
- Avenue Therapeutics to present preclinical in vivo data on BAER-101
